<abstract xmlns="http://www.w3.org/1999/xhtml">

<bold>Objective.</bold> This study was aimed to evaluate the prevalence of Cushing’s syndrome and the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients.
<bold>Methods.</bold> Anthropometric measurements and other laboratory data, including 1 mg dexamethasone suppression test of 753 class 3 obese patients, who applied to the Endocrinology and Metabolism Outpatient Clinic for the pre-bariatric surgery evaluation between 2011 and 2020, were evaluated retrospectively.
<bold>Results.</bold> An abnormal response to the 1 mg dexamethasone suppression test (cortisol ≥1.8 mcg/dl) was observed in 24 patients and the presence of Cushing’s syndrome was confirmed by additional tests in 6 patients. The prevalence of abnormal dexamethasone suppression test was 3.18% and the prevalence of Cushing’s syndrome 0.79%. The specificity value was determined as 97.5% for 1 mg dexamethasone suppression test with cortisol threshold value ≥1.8 mcg/dl.
<bold>Conclusions.</bold> The prevalence of Cushing’s syndrome was found to be low in class 3 obese patients and 1 mg of dexamethasone suppression test had a very sufficient performance for Cushing’s syndrome screening in this patient group.
</abstract>

Objective. This study was aimed to evaluate the prevalence of Cushing’s syndrome and the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients.
Methods. Anthropometric measurements and other laboratory data, including 1 mg dexamethasone suppression test of 753 class 3 obese patients, who applied to the Endocrinology and Metabolism Outpatient Clinic for the pre-bariatric surgery evaluation between 2011 and 2020, were evaluated retrospectively.
Results. An abnormal response to the 1 mg dexamethasone suppression test (cortisol ≥1.8 mcg/dl) was observed in 24 patients and the presence of Cushing’s syndrome was confirmed by additional tests in 6 patients. The prevalence of abnormal dexamethasone suppression test was 3.18% and the prevalence of Cushing’s syndrome 0.79%. The specificity value was determined as 97.5% for 1 mg dexamethasone suppression test with cortisol threshold value ≥1.8 mcg/dl.
Conclusions. The prevalence of Cushing’s syndrome was found to be low in class 3 obese patients and 1 mg of dexamethasone suppression test had a very sufficient performance for Cushing’s syndrome screening in this patient group.

Assessment of the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients

Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine

Department Biochemistry, Faculty of Medicine

Department of Surgery, Faculty of Medicine

Endocrine Regulations

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Objective. This study was aimed to evaluate the prevalence of Cushing’s syndrome and the diagnostic performance of the 1 mg dexamethasone suppression test in...

Assessment of the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients

Published Online: Oct 20, 2022

Page range: 265 - 270

DOI: https://doi.org/10.2478/enr-2022-0028

Keywords
obesity, Cushing’s syndrome, screening, dexamethasone suppression test

© 2022 Suleyman Baldane et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Assessment of the diagnostic performance of the 1 mg dexamethasone suppression test in class 3 obese patients

Published Online: Oct 20, 2022

Page range: 265 - 270

DOI: https://doi.org/10.2478/enr-2022-0028

Keywordsobesity, Cushing’s syndrome, screening, dexamethasone suppression test

© 2022 Suleyman Baldane et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Keywords
obesity, Cushing’s syndrome, screening, dexamethasone suppression test